Rosenfeld David M, Betcher Jeffrey A, Shah Ruby A, Chang Yu-Hui H, Cheng Meng-Ru, Cubillo Efrain I, Griffin Julia M, Trentman Terrence L
Department of Anesthesiology, Mayo Clinic Arizona Hospital, Mayo Medical School, Phoenix, Arizona, U.S.A.
Department of Pharmacy, Mayo Clinic Arizona Hospital, Mayo Medical School, Phoenix, Arizona, U.S.A.
Pain Pract. 2016 Mar;16(3):327-33. doi: 10.1111/papr.12277. Epub 2015 Jan 7.
Analyzing hospital naloxone use may assist in identification of areas for quality and safety improvement. Our primary objective is to quantitate the incidence of hospital naloxone use and to assess certain patient populations at risk.
During the years 2008 to 2011, each clinical scenario where naloxone was administered on an in-patient care ward was reviewed. The events were assessed to separate situations where naloxone rescue was effective in reversing opioid-induced intoxication vs. others. Further analysis was conducted to stratify patient populations at greatest risk.
Naloxone was administered for well-defined opioid-induced respiratory depression and oversedation 61% of the time, the remainder used for patient deterioration of other etiology. Surgical populations are at risk with an incidence of 3.8/1,000 hospitalized patients, and this is the greatest within 24 hours of surgery. General surgical patients represent the highest surgical patient risk at 5.5/1,000. Medical patients represent lower risk at 2.0/1,000. Patients with patient-controlled analgesia and epidural opioid infusion are high risk at 12.1 and 13.1/1,000 patients, respectively. Many quality and safety interventions were gradually implemented in response to this data and are summarized. These include nursing and provider education, electronic medical record modification, and more stringent patient monitoring practices.
Examination of naloxone use can assist in the identification and stratification of patients at risk for opioid-induced respiratory depression and oversedation and can serve as a driver for improvements in hospital patient safety. This information can also guide other institutions interested in similar improvements.
分析医院纳洛酮的使用情况有助于确定质量和安全改进的领域。我们的主要目标是量化医院纳洛酮的使用发生率,并评估某些高危患者群体。
回顾2008年至2011年期间在住院病房使用纳洛酮的每个临床场景。对这些事件进行评估,以区分纳洛酮抢救有效逆转阿片类药物引起的中毒的情况与其他情况。进一步分析以对风险最高的患者群体进行分层。
61%的情况下,纳洛酮用于明确的阿片类药物引起的呼吸抑制和过度镇静,其余用于其他病因导致的患者病情恶化。手术患者群体有风险,住院患者发生率为3.8/1000,且在手术后24小时内发生率最高。普通外科患者风险最高,为5.5/1000。内科患者风险较低,为2.0/1000。使用患者自控镇痛和硬膜外阿片类药物输注的患者风险较高,分别为12.1和13.1/1000患者。针对这些数据逐渐实施了许多质量和安全干预措施,并进行了总结。这些措施包括护理和医护人员教育、电子病历修改以及更严格的患者监测措施。
检查纳洛酮的使用情况有助于识别和分层有阿片类药物引起的呼吸抑制和过度镇静风险的患者,并可推动医院患者安全的改善。这些信息也可指导其他有类似改进意愿的机构。